Nova Scotia has decided to fund Lucentis, the leading anti-vegf drug used for treating macular degeneration. Nova Scotia Health Minister Maureen MacDonald made the announcement about the macular degeneration treatment.
The program to fund Lucentis for Nova Scotia macular degeneration patients would cost approximately $660,000 to establish and $3.5 million in 2011.
The treatment for macular degeneration (AMD) would not be subject to dispensing fees and would be provided by the necessary eye care specialists throughout Nova Scotia. Administration of Lucentis would take place in clinical settings throughout Nova Scotia to ensure better results for those suffering from the eye disease.
With the establishment of this funding program, it is estimated approximately 800 macular degeneration patients in Nova Scotia could be treated with Lucentis.
Dr. Alan Cruess, District Chief of Ophthalmology and Visual Sciences expressed caution at the numbers that may be cured by the macular degeneration drug Lucentis, indicating that sometimes the drug is ineffective. However, he did indicate that both Avastin and Lucentis are effective against wet macular degeneration.
With this funding announcement, Nova Scotians now have options to combat this retinal eye disease.